Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study uncovers genes contributing to Thoroughbred fractures
Approximately 60 horses euthanised on racecourses due to fractures each year.
Researchers identified 112 genes which regulate the bone matrix.

New research from the Royal Veterinary College (RVC) has identified 112 genes which might be contributing to bone fracture risk among Thoroughbred horses.

Although a large number of these genes have never been studied, researchers were able to demonstrate how these genes regulate the bone matrix.

Due to the force that their bones can experience, Thoroughbred horses are particularly susceptible to bone fractures. The complexity of the condition means that fractures are also a leading cause of euthanasia, with approximately 60 horses euthanised at UK racecourses each year.

This genetic study is the second of a series from RVC, as it explores the genetic mechanisms behind fracture risk.

The project saw a group of researchers utilise a polygenic risk score for fracture risk, using it to establish a new model examining how stem cells make bone-forming cells for horses at high and low risk of bone fracture.

Using this model, a team of researchers measured every gene that was expressed by the cells. This would then identify the genes with different expression levels in bone cells of horses with higher or lower risk of fractures.

Researchers were able to identify 112 genes involved in fracture risk and demonstrate how these genes regulate the bone matrix.

Many of these genes have not been studied before and so more research is needed to understand their function in bone cells. Additional research is also being conducted to validate the new risk-scoring system in another group of horses.

Debbie Guest, senior research fellow at RVC, said: “In this study, we have identified many new genes which have altered expression in bone cells from high-risk horses.

“For some of these genes, we know that they play a role in regulating the bone matrix. We can now begin to develop a deeper understanding of how bone tissue is altered in high-risk horses and new interventions to reduce their risk.”

The first study in the research series discovered that collagen type III, required for normal bone formation, was expressed at lower levels in the bone cells from horses at high genetic risk of fracture. This is as a result of a change in their DNA sequences affecting how much collagen III is produced.

The latest study has been published in the journal Anim Genet. The previous study is published in the journal Animals.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.